Debiopharm Group, the Swiss-based global biopharmaceutical company and TCG Lifesciences (TCGLS) have announced the signature of an exclusive discovery collaboration to develop innovative antibiotics targeting drug-resistant bacteria for community hospital-acquired infections. Debiopharm is willing to become a key player in the area of antibacterials to fulfill the increasing need of new classes of antibiotics to overcome resistance to current treatment.
Under the terms of the agreement, TCGLS will contribute its expertise in the discovery and optimisation of lead compounds whilst Debiopharm will provide drug development expertise and fund the development programme.
“We foresee to increase our commitment in this field over the next few months through additional partnerships and investments on other innovative targets,” said David Deperthes, VP Business Development & Licensing.
“We are enthusiastic about this partnership with TCGLS for the development of novel antibiotics, their extensive experience in medicinal chemistry and infectious diseases is a major asset for the development of Debio1348. This partnership is key to us to establish a leadership position in the area of antibiotics,” said Rolland-Yves Mauvernay, President and Founder, Debiopharm Group.
Swapan Bhattacharya, Managing Director, TCG Lifesciences commented, “We are indeed excited about this programme which involves a challenging new target that could potentially address the vast incidence of nosocomial infections which plague healthcare facilities all over the world. Debiopharm’s developmental expertise combined with our medicinal chemistry capabilities and efficient discovery operations provide an attractive opportunity for accelerated discovery of novel drug candidates for clinical development.”
EP News Bureau – Mumbai